AIM ImmunoTech Inc. (0A4Y)
LSE 
Summary
0A4Y Chart
Optima Health trading 'in line' as it continues to grow UK and Ireland platform
Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N) said full-year revenue rose around 15% to approximately £121 million for the year ended 31 March 2026, in line with market expectations, as the occupational health and wellbeing services provider continued to grow its UK and Ireland platform. The AIM-listed group said adjusted EBITDA for FY26 is expected to be around 10% ahead of previous market expectations, as previously announced.
Union Jack Oil reveals takeover approach by Reabold Resources
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) announced it has received a non-binding approach from Reabold Resources PLC (AIM:RBD, FRA:AWL1) over a possible all-share takeover. The AIM-listed oil and gas company said Reabold sent an indicative offer letter on 1 June 2026 covering a possible offer for Union Jack's entire issued share capital.
Poolbeg Pharma shows clinical progress with latest updates
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into patient recruitment as interim data remains on track for summer 2026. The AIM-listed company said the trial is assessing POLB 001 as a potential preventative for cytokine release syndrome, or CRS, in around 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.
AIM ImmunoTech Inc. (0A4Y) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AIM ImmunoTech Inc. ever had a stock split?
AIM ImmunoTech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Thomas K. Equels CEO | LSE Exchange | US00901B3033 ISIN |
| US Country | 21 Employees | - Last Dividend | 10 Feb 2026 Last Split | 12 Jul 1996 IPO Date |
Overview
AIM ImmunoTech Inc. is an immuno-pharma company primarily engaged in the research and development of therapeutic treatments for a wide variety of cancers, viral diseases, and immune-deficiency disorders within the United States. The company, which was originally founded in 1966 and known as Hemispherx Biopharma, Inc., underwent a name change to AIM ImmunoTech Inc. in August 2019, marking a new phase in its operation. With its headquarters in Ocala, Florida, AIM ImmunoTech Inc. has established several strategic agreements with entities such as Amarex Clinical Research LLC, University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente, Jubilant HollisterStier, Sterling Pharma Solutions, Erasmus University Medical Center Rotterdam, Azenova, LLC, and Alcami Corporation. These collaborations underscore the company’s commitment to advancing its pipeline of innovative treatments.
Products and Services
- Ampligen
- Alferon N Injection
As AIM ImmunoTech's leading product candidate, Ampligen represents a significant advancement in the treatment of Chronic Fatigue Syndrome (CFS) with its unique composition of macromolecular ribonucleic acid molecules. Beyond CFS, the company is expanding its potential applications to a broader spectrum of diseases, including pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers. Additionally, it is being developed for conditions such as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions, showcasing the versatility of this innovative therapeutic.
This injectable formulation of natural alpha interferon offered by AIM ImmunoTech is approved for the treatment of human papillomavirus (HPV) infections and genital warts, a common sexually transmitted disease. Alferon N Injection highlights the company's commitment to addressing a range of infectious diseases with effective treatment options.
